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Abstract
Background: Low adherence is a key factor in explaining impaired effectiveness and efficiency in
the pharmacological treatment of hypertension. However, little is known about which factors
determine low adherence in actual practice.
The purpose of this study is to examine whether low social participation is associated with low
adherence with antihypertensive medication, and if this association is modified by the municipality
of residence.
Methods: 1288 users of antihypertensive medication were identified from The Health Survey in
Scania 2000, Sweden. The outcome was low adherence with antihypertensives during the last two
weeks. Multilevel logistic regression with participants at the first level and municipalities at the
second level was used for analyses of the data.
Results: Low social participation was associated with low adherence with antihypertensives during
the last two weeks (OR = 2.05, 95% CI: 1.05–3.99), independently of low educational level.
However, after additional adjustment for poor self-rated health and poor psychological health, the
association between low social participation and low adherence with antihypertensives during the
last two weeks remained but was not conclusive (OR = 1.80, 95% CI: 0.90–3.61). Furthermore, the
association between low social participation and low adherence with antihypertensives during the
last two weeks varied among municipalities in Scania (i.e., cross-level interaction).
Conclusion:  Low social participation seems to be associated with low adherence with
antihypertensives during the last two weeks, and this association may be modified by the
municipality of residence. Future studies aimed at investigating health-related behaviours in general
and low adherence with medication in particular might benefit if they consider area of residence.
Background
The effectiveness [1,2] and efficiency [3] of antihyperten-
sives may be questioned, as adherence with antihyperten-
sives may be as low as 50% [1,4]. The efficacy of
antihypertensives has been evaluated in randomised clin-
ical trials (RCTs). The RCTs are often of short duration, the
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study population is usually carefully selected and patients
with co-morbidity or advanced ages are often excluded
from these trials [5-8]. Furthermore, even though drop-
outs and lost to follow up occur in RCTs, adherence with
medication treatment is often actively supported. In
actual practice, however, many patients, who would be
excluded from RCTs, receive medication [2] for a long
time and may not be as adherent with medication as those
included in RCTs [5].
Low adherence is one important cause of uncontrolled
hypertension [9,10]. Yet, low adherence is sometimes
unrecognised [11] and is often interpreted as treatment
resistance [10,12,13]. However, little is known about
which factors determine low adherence in actual practice
[14,15]. The purpose of this study is to examine whether
low social participation is associated with low adherence
with antihypertensives during the last two weeks, and if
this association is modified by the municipality of
residence.
Social participation is an important concept for under-
standing the influence of social factors on individual
health and behaviour, and can be viewed as a feature of
individual social networks [16]. Good social networks
have been suggested to influence health behaviours, pos-
sibly through information exchange and establishment of
health-related group norms [17]. Accordingly, a high level
of social participation may facilitate adherence [16] and
this association could be modified by the area of residence
[18,19].
Multilevel analysis handles both the micro-scale of people
and the macro-scale of context simultaneously within one
model [20]. This analytic approach has been suggested as
an interesting tool in pharmacoepidemiology [21].
The first aim of this study is to examine whether low social
participation is associated with low adherence with anti-
hypertensives during the last two weeks, independently of
low educational level and health status (i.e., poor self-
rated health and poor psychological health). The second
aim is to analyse whether the hypothesised association
between low social participation and low adherence with
antihypertensives during the last two weeks varies
between municipalities in Scania.
Methods
Participants
The Health Survey in Scania 2000 (HSS-2000) was a
postal self-administered questionnaire sent out to a ran-
dom sample of 23 437 individuals born from 1919 to
1981 living in Scania. The purpose of the HSS-2000 was
to obtain information about health conditions and differ-
ent types of health hazards among the inhabitants of
Scania [22]. The province of Scania in southern Sweden
has a population of about 1.2 million inhabitants and is
divided into 33 municipalities. In total, 59% participated,
of which 98% had complete information about medica-
tion use. The present study focused on those 9.6% who
indicated use of antihypertensives during the last year and
who had complete information about social participation
(n = 1288).
The Ethical Committee at the Medical Faculty of Lund
University approved the study proposal of The HSS-2000,
and all of the participants received written information
about the survey.
Outcome variable
Use of antihypertensives was based on an affirmative
answer to the question "Have you during the last year
used medicine, which was bought at the pharmacy...?"
and indicating "Medication for high blood pressure"
Low adherence with antihypertensives during the last two weeks
(dichotomised) was based on the question "Have you
used (this) medicine during the last year, but not during
the last 2 weeks?" Those participants who answered yes
were considered to have low adherence.
Explanatory variables
Age was categorised in five groups: <35 (reference), 35–
44, 45–54, 55–64 and ≥  65 years.
Low social participation (dichotomised) was assessed after
the respondent stated involvement in three or fewer activ-
ities (lowest quartile) of 13 formal or informal activities
(study circle/course at work place, other study circle/
course, union meeting, meeting of other organisations,
theatre/cinema, arts exhibition, church, sports event, let-
ter to editor of a newspaper/journal, demonstration, night
club/entertainment, large gathering of relatives, private
party), which the respondent might have participated in
during the previous 12 months [23].
Low educational level (dichotomised) was defined as hav-
ing nine years of education or less.
Poor self-rated health (dichotomised) was defined as a
value of ≤  3 on an ordinal self-rated health scale ranging
from 1 ("Very bad") to 7 ("Very good") [24].
Poor psychological health (dichotomised) was determined
by giving three or more affirmative answers to the 12
items composing the Standardised General Health Ques-
tionnaire (GHQ-12) [25].BMC Public Health 2005, 5:17 http://www.biomedcentral.com/1471-2458/5/17
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Statistical analysis
Because of the hierarchy in the data, with individuals
nested in municipalities, we used multilevel logistic
regression [26] with individuals at the first level and
municipalities at the second level. The area of residence
might affect a person's social participation [27], and, con-
sequently, it may be possible that the influence of low
social participation on low adherence with antihyperten-
sives during the last two weeks may vary between munic-
ipalities. Therefore, we let the slopes of the association
between low social participation and low adherence vary
at the municipality level. This random slopes analysis
gives information about whether the association between
low social participation and low adherence is different in
different municipalities.
The first model i was created to study the influence of low
social participation on low adherence with antihyperten-
sives during the last two weeks, adjusting for age and sex.
The second model ii was extended to also include low
educational level, because low educational level could be
a confounder in the association between low social partic-
ipation and low adherence with antihypertensives during
the last two weeks. The third model iii additionally con-
tained poor self-rated health and poor psychological
health. Impaired health may affect both low social partic-
ipation and low adherence with antihypertensives.
Fixed effects
The results are shown as odds ratios (OR) with 95% con-
fidence intervals (CI)
Random effects
We calculated the second level variance (variation
between municipalities) regarding prevalence of low
adherence with antihypertensives during the last two
weeks (i.e., the intercepts in the multilevel regression),
and the second level variance regarding the association
between low social participation and low adherence with
antihypertensives during the last two weeks (i.e., the slope
variance in the multilevel regression). We also calculated
the covariance between intercept and slope residuals. The
covariance gives information about whether the associa-
tion between low social participation and low adherence
with antihypertensives during the last two weeks depends
on the prevalence of low adherence in the different
municipalities (i.e., cross-level interaction).
Parameters were estimated using the Restricted Iterative
Generalized Least Squares (RIGLS) and penalised quasi-
likelihood (PQL). Extra-binomial variation was explored
systematically in all models and we found no evidence for
under- or over-dispersion. The MLwiN, Version 1.1 soft-
ware package [28] was used for the analyses.
Results
Low adherence with antihypertensives during the last two
weeks was found among 11% (145/1 288) of the
participants and 49% (635/1 288) were classified as hav-
ing low social participation. The participants mean age
was 63 years. Those participants classified as having low
social participation more often reported low adherence
with antihypertensives during the last two weeks, low
educational level, poor self-rated health and poor psycho-
logical health than those who were not classified as hav-
ing low social participation (Table 1).
Fixed effects
Participants with low social participation had on average
a more than twofold higher probability of reporting low
adherence with antihypertensives during the last two
weeks than those who did not have low social participa-
tion (OR = 2.28, 95% CI: 1.16–4.49) (Table 2). This asso-
ciation between low social participation and low
Table 1: Characteristics of the participants (n = 1288) according to individual low social participation.
Low social participation
Yes (n = 635)
No. (%)
No (n = 653)
No. (%)
Total (n= 1288)
No. (%)
Age (mean years) 65 60 63
Women 340 (54) 346 (53) 686 (53)
Low adherence with antihypertensives 96 (15) 49 (8) 145 (11)
Low educational level 417 (70) 284 (45) 701 (57)
Poor self-rated health 112 (19) 64 (10) 176 (14)
Poor psychological health 124 (21) 95 (15) 219 (18)BMC Public Health 2005, 5:17 http://www.biomedcentral.com/1471-2458/5/17
Page 4 of 7
(page number not for citation purposes)
adherence with antihypertensives during the last two
weeks persisted after adjusting for low educational level
(OR = 2.05, 95% CI: 1.05–3.99). However, after addi-
tional adjustment for poor self-rated health and poor psy-
chological health, the association between low social
participation and low adherence with antihypertensives
during the last two weeks was not conclusive using a 95%
confidence interval (OR = 1.80, 95% CI: 0.90–3.61).
Random effects
We found a variance between the municipalities in both
low adherence with antihypertensives during the last two
weeks (intercept variance) and in the association between
low social participation and low adherence with antihy-
pertensives during the last two weeks (slope variance)
(Table 2 and Figure 1). The negative covariance between
intercepts and slopes (Table 2) suggested that the associa-
tions between low social participation and low adherence
with antihypertensives during the last two weeks (slopes)
in the 33 municipalities depended on different prevalence
of low adherence with antihypertensives during the last
two weeks in the different municipalities. The association
between low social participation and low adherence with
antihypertensives during the last two weeks (slope) was
weaker in municipalities with higher prevalence than in
municipalities with lower prevalence of low adherence
with antihypertensives during the last two weeks (i.e.,
cross-level interaction).
Discussion
Main findings
Our results suggest that low social participation is associ-
ated with low adherence with antihypertensives during
the last two weeks, independently of low educational
level. In other words, the association between low social
participation and low adherence withstood adjustment
Table 2: Municipality variance and age adjusted odds ratios (95% confidence intervals) of low adherence with antihypertensives during 
the last two weeks in relation to sex, low social participation, low educational level, poor self-rated health and poor psychological 
health.
Model i Model ii Model iii
OR 95% CI OR 95% CI OR 95% CI
Women vs. men 1.21 (0.82–1.78) 1.15 (0.78–1.69) 1.17 (0.78–1.77)
Low social participation (yes vs. no) 2.28 (1.16–4.49) 2.05 (1.05–3.99) 1.80 (0.90–3.61)
Low educational level (yes vs. no) 1.87 (1.18–2.96) 1.76 (1.09–2.84)
Poor self-rated health (yes vs. no) 1.45 (0.83–2.54)
Poor psychological health (yes vs. no) 1.54 (0.92–2.59)
Variance SE Variance SE Variance SE
Municipality variance in low adherence with 
antihypertensives (intercept variance)
0.801 (0.461) 0.776 (0.450) 0.793 (0.467)
Municipality variance of the association between low social 
participation and low adherence with antihypertensives 
(slope variance)
1.812 (0.889) 1.720 (0.857) 1.799 (0.916)
Municipality covariance between intercepts and slopes -1.163 (0.609) -1.116 (0.591) -1.175 (0.625)
Slope variance in the association between low social partici- pation and low adherence with antihypertensives during the  last two weeks among 33 municipalities in Scania, Sweden Figure 1
Slope variance in the association between low social partici-
pation and low adherence with antihypertensives during the 
last two weeks among 33 municipalities in Scania, Sweden.
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for socio-economic position (expressed by educational
level) in our analyses. Social participation might therefore
be considered as a real construct, and not only a proxy for
socio-economic position. However, the association
between low social participation and low adherence with
antihypertensives during the last two weeks was weakened
after additional adjustment for poor self-rated health and
poor psychological health. Furthermore, the association
between low social participation and low adherence with
antihypertensives during the last two weeks may vary
between municipalities in Scania.
The weakening of the association between low social par-
ticipation and low adherence with antihypertensives dur-
ing the last two weeks after we adjusted for poor self-rated
health and poor psychological health may be an expres-
sion for confounding. Impaired health may negatively
affect both social participation and adherence with anti-
hypertensives. On the other hand, the observed reduction
of the association may instead be telling us that physical
and mental health are in the pathway between low social
participation and low adherence with antihypertensives
during the last two weeks [29]. Social participation may
be considered as an early factor in the causal pathway that
determines individual health-related behaviour, such as
low adherence with medication. Social networks, which
are connected to social participation, may promote shared
norms around health behaviours, as treatment adherence,
which could explain the pathway between social networks
and impaired health [16].
Our present finding that the association between low
social participation and low adherence with antihyperten-
sives during the last two weeks may vary between munic-
ipalities in Scania gives empirical support to the existence
of cross-level interactions (i.e., between municipality and
individual) associated with health-related behaviours,
such as low adherence with medication. These behaviours
may be a result of the interaction between a person and
his or her area of residence [18]. In a previous analysis, we
observed that both individual and neighbourhood social
participation are associated with individual impaired
health and with use of hormone replacement therapy in
women [18].
The present study shows that multilevel regression analy-
sis can be used for investigation of geographical dispari-
ties in health and health-related behaviour (e.g,
adherence with medication), without analysing any spe-
cific area characteristic [30]. In multilevel analysis, area
effects can be investigated by measures of variance and by
examining how area boundaries modify individual level
associations [31].
Limitations of the study
The rather low participation rate (59%) may increase the
risk of selection bias and reduce the ability to generalise
the results and compare them to other populations. Nev-
ertheless, the participation rate for participants aged 51–
80 was about 65% and the participants using antihyper-
tensives had a mean age of 63 years.
The low adherence question we used was stated in a non-
threatening manner, which might facilitate for partici-
pants to give an honest response and not underreport low
adherence [32]. Self-reported adherence has been
reported to correlate with clinical measures of disease
activity and control [4]. Moreover, self-report offers a con-
venient and non-invasive estimate of adherence behav-
iour. Nevertheless, the procedure of measuring adherence
is controversial. Self-report can be subject to self-presenta-
tional and recall biases. People may overestimate their
adherence and their memory may be inaccurate [32]. We
might have reduced memory bias in this study by restrict-
ing the recall time to two weeks. However, the prevalence
of current low adherence (11%) in this study is lower than
low adherence reported in a longer period of time, which
may be as high as 50% [1,4]. Therefore, our results may
underestimate the association between social participa-
tion and low adherence with antihypertensives. It is pos-
sible that some participants with high adherence in the
last two weeks had low adherence in other periods of the
year. If this kind of misclassification would be more fre-
quent among participants with low social participation,
there would be differential misclassification, and the asso-
ciation between low social participation and adherence
with antihypertensives could be underestimated. Non-dif-
ferential misclassification would also underestimate the
association between low social participation and low
adherence with antihypertensives. Other ways of measur-
ing adherence may be more appropriate, such as
Morisky's four-item scale [33], which will be used in the
Health Survey for Scania 2004.
People with low social participation and low adherence
with antihypertensives during the last two weeks may
have been less inclined to respond to the HSS-2000 ques-
tionnaire. This possible selection bias could lead to an
underestimation of the association between low social
participation and low adherence with antihypertensives
during the last two weeks.
Conclusion
Our results suggest that low social participation is associ-
ated with low adherence with antihypertensives during
the last two weeks, independently of low educational
level. In addition, the association between low social par-
ticipation and low adherence with antihypertensives dur-
ing the last two weeks seems to vary between theBMC Public Health 2005, 5:17 http://www.biomedcentral.com/1471-2458/5/17
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municipalities in Scania, which gives empirical support to
the existence of cross-level interactions (i.e., between
municipality and individual) associated with health-
related behaviours, such as low adherence with medica-
tion. We have recently showed that factors related to the
area of residence influence the individual blood pressure
level, especially in people using antihypertensive medica-
tion [34], which is in concordance with the results of this
present study.
Future studies aimed at investigating health-related
behaviours in general and low adherence with medication
in particular might benefit if they consider that area of res-
idence may modify associations between individual
variables.
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